Advances in Therapy

, Volume 27, Issue 6, pp 348–364 | Cite as

Systematic review on evidence of the effectiveness of cholesterol-lowering drugs

  • Abhaya Gupta
  • Veronique Guyomard
  • M. Justin S. Zaman
  • Habib U. Rehman
  • Phyo Kyaw Myint
Review

Abstract

Introduction

Coronary heart disease (CHD) is the leading cause of mortality worldwide. With increasingly urbanized lifestyles in developing countries and the aging populations, the major risk factors for CHD such as obesity, diabetes mellitus, and hypercholesterolemia are likely to increase in the future. In the current report, we reviewed the evidence on the effect of cholesterol lowering using pharmacological agents.

Methods

A PubMed/Medline systematic search was performed over the past 12 years (1998–2009 inclusive) and relevant papers written in the English language were selected. We used key phrases including, “risk factors for hypercholesterolemia,” “management of hypercholesterolemia,” “guidelines for management of hypercholesterolemia,” and “pharmacological management of hypercholesterolemia.”

Results

There were a total of over 3500 reports. We selected key publications on the effect of cholesterol lowering using different pharmacological agents.

Conclusion

Several options exist with regards to pharmacological management of hypercholesterolemia. There is a substantial body of evidence to support the effect of a population shift towards a favorable risk profile, which has huge potential in reducing the burden of CHD globally.

Keywords

cardiovascular disease cholesterol-lowering drugs coronary heart disease hypercholesterolemia risk 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    DOH web site. Coronary heart disease. Policy and guidance. London: Department of Health. Available at: http://www.dh.gov.uk/PolicyAndGuidance/HealthAndSocialCareTopics/CoronaryHeartDisease/fs/en. Last accessed February 24, 2010.
  2. 2.
    Lloyd-Jones DM, Larson MG, Beiser A, et al. Lifetime risk of developing coronary heart disease. Lancet. 1999;353:89–92.PubMedCrossRefGoogle Scholar
  3. 3.
    Verschuren WMM, Jacobs DR, Bloemberg BPM, et al. Serum total cholesterol and long term coronary heart disease mortality in different cultures: twenty five year follow up of the Seven Country Study. JAMA. 1995;274:131–136.PubMedCrossRefGoogle Scholar
  4. 4.
    American Heart Association, National Heart, Lung, and Blood Institute. The cholesterol facts: a summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. Circulation. 1990;81:1721–1733.Google Scholar
  5. 5.
    Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1994;308:367–372.PubMedGoogle Scholar
  6. 6.
    Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497.Google Scholar
  7. 7.
    Wood D. Joint British Societies guidelines on prevention of cardiovascular disease in clinical practice. JBS-2. Heart. 2005;91(suppl. V):1–2.Google Scholar
  8. 8.
    Brown MS, Faust JR, Goldstein JL. Inhibition of 3-hydroxy 3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. J Biol Chem. 1978;253:1121–1128.PubMedGoogle Scholar
  9. 9.
    Brown MS, Goldstein GL. A receptor mediated pathway for cholesterol homeostasis. Science. 1986;232:34–47.PubMedCrossRefGoogle Scholar
  10. 10.
    Berglund LF, Beltz WF, Elam RL, Witztum JL. Altered apolipoprotein B metabolism in very low density lipoprotein from lovastatin-treated guinea pigs. J Lipid Res.1994;35:956–965.PubMedGoogle Scholar
  11. 11.
    Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease and stroke: systematic review and meta-analysis. BMJ. 2003;326:1423.PubMedCrossRefGoogle Scholar
  12. 12.
    Chong PH, Kezele R, Franklin C. High-density lipoprotein cholesterol and the role of statins. Circ J. 2002;66:1037–1044.PubMedCrossRefGoogle Scholar
  13. 13.
    The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–1357.CrossRefGoogle Scholar
  14. 14.
    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Society of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.CrossRefGoogle Scholar
  15. 15.
    La Rosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–1435.CrossRefGoogle Scholar
  16. 16.
    Nissen S, Nicholls S, Siphai I, et al. Effect of very high intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295:1556–1565.PubMedCrossRefGoogle Scholar
  17. 17.
    Takemoto M, Liao JK. Pleotropic effects of 3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vas Biol. 2001;21:1712.CrossRefGoogle Scholar
  18. 18.
    Gylling H, Miettinen TA. Baseline intestinal absorption and synthesis of cholesterol regulate its response to hypolipidaemic treatments in coronary patients. Atherosclerosis. 2002;160:477–478.PubMedCrossRefGoogle Scholar
  19. 19.
    Olsson AG, Eriksson M, Johnson O, et al. A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study. Clin Ther. 2003;25:119–138.PubMedCrossRefGoogle Scholar
  20. 20.
    Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92:152–160.PubMedCrossRefGoogle Scholar
  21. 21.
    Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia — the CURVES study. Am J Cardiol. 1998;81:582–587.PubMedCrossRefGoogle Scholar
  22. 22.
    Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin related adverse events: a meta-analysis. Clin Ther. 2006;28:26–35.PubMedCrossRefGoogle Scholar
  23. 23.
    Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin induced myopathy — a genomewide study. N Engl J Med. 2008;8:789–799.Google Scholar
  24. 24.
    Kane GC, Lipsky JJ. Drug grapefruit juice interactions. Mayo Clin Proc. 2000;75:933–942.PubMedCrossRefGoogle Scholar
  25. 25.
    De Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative Simvastatin strategy in patients with acute coronary syndromes. Phase Z of the A to Z Trial. JAMA. 2004;292:1307–1316.PubMedCrossRefGoogle Scholar
  26. 26.
    Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalised rhabdomyolysis in patients treated with lipid lowering drugs. JAMA. 2004;292:2585–2590.PubMedCrossRefGoogle Scholar
  27. 27.
    Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: a meta-analysis. JAMA. 2006;295:74–80.PubMedCrossRefGoogle Scholar
  28. 28.
    Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH. Effect of magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis and cancer: insights from large randomised statin trials. J Am Coll Cardiol. 2007;50:409–418.PubMedCrossRefGoogle Scholar
  29. 29.
    Einarsson K, Ericsson S, Ewerth S, et al. Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism. Eur J Clin Pharmacol. 1991;40(suppl. 1):S53–S58.PubMedCrossRefGoogle Scholar
  30. 30.
    Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999;341:498–511.PubMedCrossRefGoogle Scholar
  31. 31.
    Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988;260:641–651.PubMedCrossRefGoogle Scholar
  32. 32.
    Rubins, Bloomfield H, Davenport J, et al. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol. The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation. 2001;103:2828–2833.Google Scholar
  33. 33.
    [No authors listed]. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the BIP study. Circulation. 2000;102:21–27.Google Scholar
  34. 34.
    Vakkilainen J, Steiner G, Ansquer JC, et al. Relationships between LDL particle size, plasma lipoproteins and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DIAS). Circulation. 2003;107:1733–1737.PubMedCrossRefGoogle Scholar
  35. 35.
    FIELD Study Investigators. Effects of longterm fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study) randomised controlled trial. Lancet. 2005;366:1849–1861.CrossRefGoogle Scholar
  36. 36.
    Kind AH, Zakowski LJ, McBride PE. Rhabdomyolysis from the combination of a statin and gemfibrozil: an uncommon but serious adverse reaction. WMJ. 2002;101:53–56.PubMedGoogle Scholar
  37. 37.
    McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained vs. immediate-release niacin in hypercholesterolemic patients. JAMA. 1994;271:672–677.CrossRefGoogle Scholar
  38. 38.
    Rosenson RS. Antiatherothrombotic effects of nicotinic acid. Atherosclerosis. 2003;171:87–96.PubMedCrossRefGoogle Scholar
  39. 39.
    Canner PL, Berge KG, Wenger N, et al. Fifteen year mortality in Coronary Drug Project patients: long term benefit with niacin. J Am Coll Cardiol. 1986;8:1245–1255.PubMedCrossRefGoogle Scholar
  40. 40.
    Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289–1298.PubMedGoogle Scholar
  41. 41.
    Grundy SM, Vega GI, McGovern MI, et al. Efficacy, safety and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Arch Intern Med. 2002;162:1568–1576.PubMedCrossRefGoogle Scholar
  42. 42.
    Temel RE, Tang W, Ma Y, et al. Hepatic Niemann-Pick C1 like 1 regulates biliary cholesterol concentration and is target of ezetimibe. J Clin Invest. 2007;117:1968–1978.PubMedCrossRefGoogle Scholar
  43. 43.
    Knopp RH, Gitter H, Truitt T, et al. Ezetimibe Study Group. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J. 2003;24:729–741.PubMedCrossRefGoogle Scholar
  44. 44.
    Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of potent new selective cholesterol absorption inhibitor, ezetimibe in patients with primary hypercholesterolemia. Am J Cardiol. 2002;90:1092–1097.PubMedCrossRefGoogle Scholar
  45. 45.
    Thomsen AB, Hasen HB, Christiansen C, Green H, Berger A. Effect of free plant sterols in low-fat milk on serum lipid profile in hypercholesterolemic subjects. Eur J Clin Nutr. 2004;58:860–870.PubMedCrossRefGoogle Scholar
  46. 46.
    Patch CS, Tapsell LC, Williams PG. Plant sterol/stanol prescription is an effective treatment strategy for managing hypercholesterolemia in outpatient clinical practice. J Am Diet Assoc. 2005;105:46–52.PubMedCrossRefGoogle Scholar
  47. 47.
    Plat J, Mensink RP. Plant stanol and sterol esters in the control of blood cholesterol levels: mechanism and safety aspects. Am J Cardiol. 2005;96:15–22.CrossRefGoogle Scholar
  48. 48.
    Kreisberg RA, Oberman A. Medical management of hyperlipidemia/dyslipidemia. J Clin Endocrinol Metab. 2003;88:2445–2461.PubMedCrossRefGoogle Scholar
  49. 49.
    Yashodhra BM, Umakanth S, Pappachan JH. Omega 3 fatty acids: a comprehensive review of their role in health and disease. Postgrad Med J. 2009;85:84–90.CrossRefGoogle Scholar
  50. 50.
    Hu BF, Brouner L, Willet W. Fish and omega 3 fatty acids intake and risk of coronary heart disease in women. JAMA. 2002;287:1815–1821.PubMedCrossRefGoogle Scholar
  51. 51.
    Albert C, Hennekem CH, O’Donnell C, et al. Fish consumption and risk of sudden cardiac death. JAMA. 1998;279:23–28.PubMedCrossRefGoogle Scholar
  52. 52.
    Marchioli R, Barzi F, Bomba E, et al. GISSI Prevenzione Investigators. Early protection against sudden death by polyunsaturated fatty acids after myocardial infarction. Circulation. 2002;105:1897–1903.PubMedCrossRefGoogle Scholar
  53. 53.
    Yokoyama H, Origasa H, Matsuzaki M, et al. JELIS Investigators. Effects of EPA on major coronary events in hypercholesterolemic patients. Lancet. 2007;369:1090–1098.PubMedCrossRefGoogle Scholar
  54. 54.
    Hooper L, Thompson RL, Harrison RA, et al. Risks and benefits of O3FA for mortality, cardiovascular disease and cancer: systematic review. BMJ. 2006;333:752–760.CrossRefGoogle Scholar
  55. 55.
    Hooper L, Thompson RL, Harrison RA, et al.Omega 3 fatty acids for prevention and treatment of CVD. Cochrane Database Syst Rev. 2004;(4):CD003177.Google Scholar
  56. 56.
    Mozaffarian D, Rimm EB. Fish intake, contaminants and human health: evaluating risks and benefits. JAMA. 2006;296:1885–1899.PubMedCrossRefGoogle Scholar
  57. 57.
    Gapinski JP, Van Ruiswyk JV, Hendebert GR, et al. Preventing restenosis with fish oils following coronary angioplasty. A meta-analysis. Arch Intern Med. 1993;153:1595–1601.PubMedCrossRefGoogle Scholar
  58. 58.
    Lee IM, Cook NR, Gaziana JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Womens Health Study: a randomised controlled trial. JAMA. 2002;288:322–333.Google Scholar
  59. 59.
    Hulley S, Grady D, Bush T, et al. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. HERS research group. JAMA. 1998;280:605–613.PubMedCrossRefGoogle Scholar
  60. 60.
    Rossouw JE, Anderson GL, Prentice RL, et al. Writing group for the Womens Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Womens Health Initiative RCT. JAMA. 2002;288:321–333.PubMedCrossRefGoogle Scholar
  61. 61.
    Estruch R, Martinez-Gonzalez MA, Corella D, et al. PREDMED Study investigators. Effects of Mediterranean style diet on cardiovascular risk factors: a randomised trial. Ann Intern Med. 2006;145:1–11.PubMedGoogle Scholar
  62. 62.
    de Lorgeril M, Salen P, Martin JL, et al. Mediterranean diet, traditional risk factors and rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation. 1999;99:779–785.PubMedGoogle Scholar
  63. 63.
    Athyros VG, Papageorgiou AA, Athyrou VV, et al. Atorvastatin and micronised fenofibrtae alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care. 2002;25:1198–1202.PubMedCrossRefGoogle Scholar
  64. 64.
    Kashyap ML, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol. 2002;89:672–678.PubMedCrossRefGoogle Scholar
  65. 65.
    Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and tolerability of simvastatin and fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol. 2005;95:462–468.PubMedCrossRefGoogle Scholar
  66. 66.
    Davidson MH. Reducing residual risk for patients on statin therapy: the potential role of combination therapy. Am J Cardiol. 2005;96:3K–13K.PubMedCrossRefGoogle Scholar
  67. 67.
    The ACCORD Investigators. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–1574.CrossRefGoogle Scholar
  68. 68.
    Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583–1592.PubMedCrossRefGoogle Scholar
  69. 69.
    Taylor AJ, Sullenberger LE, Lee HJ. Arterial Biology for the Investigation of the Treatment Effects of Cholesterol (ARBITOR-2): a double blind placebo controlled study of extended release niacin in atherosclerosis progression in secondary prevention. Patients treated with statins. Circulation. 2004;110:2–7.CrossRefGoogle Scholar
  70. 70.
    Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended release niacin on carotid intima-media thickness (ARBITER-3). Curr Med Res Opin. 2006;22:2243–2250.PubMedCrossRefGoogle Scholar
  71. 71.
    Ballantyne CM, Houri J, Notarbartolo A, et al. Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003;107:2409–2415.PubMedCrossRefGoogle Scholar
  72. 72.
    Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;40:2125–2134.PubMedCrossRefGoogle Scholar
  73. 73.
    Goldberg AC, Sapre A, Liu L, Capece R, Mitchel YB. Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2004;79:620–629.PubMedCrossRefGoogle Scholar
  74. 74.
    Catapano AL, Davidson MH, Ballantyne CM, et al. Lipid altering efficacy of ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin. 2006;22:2041–2053.PubMedCrossRefGoogle Scholar
  75. 75.
    Ballantyne CM, Weiss R, Moccetti T, et al. EXPLORER study investigators. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease — results from EXPLORER study. Am J Cardiol. 2007;99:673–680.PubMedCrossRefGoogle Scholar
  76. 76.
    Denke M, Pearson T, McBride P, et al. Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diab Vasc Dis Res. 2006;3:393–102.CrossRefGoogle Scholar
  77. 77.
    Davidson MH, Ballantyne CM, Kerzner B, et al. Efficacy and safety of ezetimibe coadministered with statins. Int J Clin Pract. 2004;58:746–755.PubMedCrossRefGoogle Scholar
  78. 78.
    Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431–1443.PubMedCrossRefGoogle Scholar
  79. 79.
    Rossebo AB, Pederson TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343–1356.PubMedCrossRefGoogle Scholar
  80. 80.
    Peto R, Emberson J, Landray M, et al. Analysis of cancer data from three ezetimibe trials. N Engl J Med. 2008;359:1357–1366.PubMedCrossRefGoogle Scholar
  81. 81.
    Taylor AJ, Villimes TC, Stanek EJ, et al. Extended release niacin or ezetimibe and carotid intima media thickness. N Engl J Med. 2009;361:2113–2122.PubMedCrossRefGoogle Scholar
  82. 82.
    Kastelein JP, Bots ML. Statin therapy with ezetimibe or niacin in high risk patients. N Engl J Med. 2009;361:2180–2183.PubMedCrossRefGoogle Scholar
  83. 83.
    Stamler J, Wentworth D, Neaton JD. Is the relation between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256:2823–2828.PubMedCrossRefGoogle Scholar
  84. 84.
    Chen Z, Peto R, Collins R, et al. Serum cholesterol concentration and coronary heart disease in a population with low cholesterol levels. BMJ. 1991;303:276–282.PubMedCrossRefGoogle Scholar
  85. 85.
    Wilson PW, Anderson KM, Castelli WP. Twelve year incidence of CHD in middle aged adults during the era of hypertensive therapy. The Framingham Offspring Study. Am J Med. 1991;90:276–282.CrossRefGoogle Scholar
  86. 86.
    Assman G, Cullen P, Schulte H. The Munster Heart Study (PROCAM): results of follow up at 8th years. Eur Heart J. 1998;19(suppl. A):A2–A11.Google Scholar
  87. 87.
    Verschuuren WM, Jacobs DR, Bloemberg BP, et al. Serum total cholesterol and long-term coronary heart disease mortality in different culture: twenty five year follow up of the seven countries study. JAMA. 1995;274:131–136.CrossRefGoogle Scholar
  88. 88.
    Rifkind BM. Lipid research clinics coronary primary prevention trial: results and implications. Am J Cardiol. 1984;54:30C–34C.PubMedCrossRefGoogle Scholar
  89. 89.
    Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with Pravastatin in men with hypercholesterolaemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301–1307.PubMedCrossRefGoogle Scholar
  90. 90.
    Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA. 1998;279:1615–1622.PubMedCrossRefGoogle Scholar
  91. 91.
    Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial — Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149–1158.PubMedCrossRefGoogle Scholar
  92. 92.
    Ridker P, Danielson E, Francisco AH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C reactive protein. N Engl J Med. 2008;359:2195–2207.PubMedCrossRefGoogle Scholar
  93. 93.
    Mills EJ, Rachlis B, Wu P, et al. Primary prevention of cardiovascular mortality and events with statin treatments. J Am Coll Cardiol. 2008;52:1769–1781.PubMedCrossRefGoogle Scholar
  94. 94.
    Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389.Google Scholar
  95. 95.
    Sachs FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trials Investigators. CARE. N Engl J Med. 1996;335:1001–1009.CrossRefGoogle Scholar
  96. 96.
    Studer M, Briel M, Leimenstoll B, et al. Effect of different antilipidemic agents and diets on mortality: a systemic review. Arch Intern Med. 2005;165:725–730.PubMedCrossRefGoogle Scholar
  97. 97.
    James H, O’Keefe Jr. Optimal LDL is 50-70 mg/dL. Lower is better and physiologically normal. J Am Coll Cardiol. 2004;43:11.Google Scholar
  98. 98.
    Ray KK, Cannon CP, McCabe CH, et al. Early and late benefits of high dose atorvastatin in patients with acute coronary syndromes: results from the PROVE-IT TIMI 22 trial. J Am Coll Cardiol. 2005;46:1405–1410.PubMedCrossRefGoogle Scholar
  99. 99.
    NHS web site. The information centre for health and social care. Prescriptions dispensed in the community 1996-2006 [NS]. Department of Health. Available at: http://www.ic.nhs.uk/statisticsand-data-collections/primary-care/prescriptions/prescriptions-dispensed-in-the-community-1996-2006-%5Bns%5D. Last accessed February 24, 2010.
  100. 100.
    NICE web site. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. Available at: http://guidance.nice.org.uk/CG67. Last accessed February 24, 2010.
  101. 101.
    Unwin N, Thomson R, O’Byrne AM, Laker M, Armstrong H. Implications of applying widely accepted cholesterol screening and management guidelines to a British adult population: cross sectional study of cardiovascular disease and risk factors. BMJ. 1998;317:1125–1130.PubMedGoogle Scholar
  102. 102.
    Cullen P, Schulte H, Assman G. The Munster Heart Study. Total mortality in middle aged men is increased at low total and LDL-C concentration in smokers but not in nonsmokers. Circulation. 1997;96:2128–2136.PubMedGoogle Scholar
  103. 103.
    Helaine E, Jones K, Ruotolo G, et al. Insulin resistance, the metabolic syndrome and risk of incident cardiovascular disease in nondiabetic American Indians. The Strong Heart Study. Diabetes Care. 2003;26:861–867.CrossRefGoogle Scholar
  104. 104.
    The ALLHAT Officers and Co-ordinators for the ALLHAT Collaborative research group. The antihypertensive and lipid lowering treatment for prevention of heart attack trial: major outcomes in moderately hypercholesterolemic hypertensive patients randomised to pravastatin or usual care. ALLHAT-LLT. JAMA. 2002;288:2998–3007.CrossRefGoogle Scholar
  105. 105.
    Farmer JA, Gotto AM Jr. The HPS: expanding the boundaries for high risk coronary disease prevention. Am J Cardiol. 2003;92:31–91.CrossRefGoogle Scholar
  106. 106.
    Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002; 360:1623–1630.PubMedCrossRefGoogle Scholar
  107. 107.
    Afilalo J, Gustavo Duque, Steele R. Statins for secondary prevention in elderly patients - a hierarchical Bayesian meta-analysis. J Am Coll Cardiol. 2008;51:37–45.PubMedCrossRefGoogle Scholar
  108. 108.
    McKeigue P M, Miller G J, Marmot MG. Coronary heart disease in South Asians overseas: a review. J Clin Epidemiol. 1989;42:597–609.PubMedCrossRefGoogle Scholar
  109. 109.
    Spriston K, Primatesta P, eds. Risk Factors for Cardiovascular Disease. Health Survey for England 2003. Vol. 2. London: The Stationery Office; 2004.Google Scholar

Copyright information

© Springer Healthcare 2010

Authors and Affiliations

  • Abhaya Gupta
    • 1
  • Veronique Guyomard
    • 2
  • M. Justin S. Zaman
    • 3
  • Habib U. Rehman
    • 4
  • Phyo Kyaw Myint
    • 5
  1. 1.Department of MedicineWest Wales HospitalCarmarthenUK
  2. 2.Ageing and Stroke Research GroupNorfolk and Norwich University HospitalNorwichUK
  3. 3.University College LondonLondonUK
  4. 4.Regina Qu”Appelle Health RegionReginaCanada
  5. 5.School of Medicine, Health Policy and PracticeUniversity of East AngliaNorwichUK

Personalised recommendations